呼吸道迟缓爱德华菌不同组分对肺部炎症作用的对比分析

doi:10.3969/j.issn.1006-7795.2023.06.020

首都医科大学学报

• 基础研究 • 上一篇

呼吸道迟缓爱德华菌不同组分对肺部炎症作用的对比分析

李琴¹，胡悦²，秦啸峰²，冯志红³，王炜²，孙英^2*

1. 首都医科大学燕京医学院检验学学系，北京 101300；2. 首都医科大学基础医学院免疫学系，北京 100069；3. 首都医科大学宣武医院呼吸内科，北京 100053

收稿日期:2023-08-19 出版日期:2023-12-20 发布日期:2023-12-20
通讯作者: 孙英 E-mail:ying.sun@ccmu.edu.cn
基金资助:
北京市自然科学基金项目（7212001)，首都医科大学燕京医学院科研培育基金项目（20kyqd04)。

Comparative study of effect of different components of Edwardsiella tarda on pulmonary inflammation

Li Qin¹, Hu Yue², Qin Xiaofeng², Feng Zhihong³, Wang Wei², Sun Ying^2*

1. Department of Laboratory, Yanjing Medical College, Capital Medical University, Beijing 101300, China; 2. Department of Immunology, School of Basic Medical Sciences, Capital Medical University, Beijing 100059, China; 3. Department of Respiratory Medicine, Xuanwu Hospital, Capital Medical University, Beijing 100053, China

Received:2023-08-19 Online:2023-12-20 Published:2023-12-20
Supported by:
This study was supported by Natural Science Foundation of Beijing(7212001)，Scientific Research Foundation of Yanjing Medical College, Capital Medical University (20kyqd04).

摘要/Abstract

摘要： 目的探讨呼吸道迟缓爱德华菌不同组分对肺部损伤的影响及其促炎作用。方法应用迟缓爱德华菌灭活菌体、裂解物和代谢物滴鼻构建小鼠急性肺损伤模型和体外细胞实验，细胞分类计数分析支气管肺泡灌洗液（bronchoalveolar lavage fluid，BALF)炎性细胞情况；酶联免疫吸附试验（enzyme-linked immunosorbent assay，ELISA)检测BALF和细胞培养上清中促炎细胞因子的表达情况；组织化学法分析肺组织中嗜酸性粒细胞和白细胞介素（interleukin，IL)33阳性细胞的浸润情况。结果迟缓爱德华菌裂解物和代谢物滴鼻组可明显诱导小鼠气道中性粒细胞和巨噬细胞增加以及促炎细胞因子IL-1β、IL-6和肿瘤坏死因子α（tumor necrosis factor α，TNF-α)分泌增多的炎症反应（P<0.05)；灭活菌体可诱导肺组织嗜酸性粒细胞和IL-33⁺细胞的浸润增加（P<0.05)。体外实验表明迟缓爱德华菌不同成分可诱导人和小鼠肺泡上皮细胞和巨噬细胞不同程度地产生促炎细胞因子（P<0.05)。结论呼吸道迟缓爱德华菌可引起肺部炎症反应，促炎细胞因子可能主要通过诱导肺泡上皮细胞和巨噬细胞产生。

关键词: 迟缓爱德华菌, 慢性阻塞性肺疾病, 炎症作用, 呼吸道

Abstract: Objective To explore the effects of different components of Edwardsiella tarda on pulmonary inflammatory responses and to clarify the potential role of Edwardsiella tarda in progression of chronic obstructive pulmonary disease(COPD), which might provide a novel theoretical basis for the pathogenesis of COPD. Methods In vivo, mice were given different components derived from Edwardsiella tarda (inactivated bodies, bacterial lysates and supernatant of cultured bacteria) intranasally to establish mice models of acute lung injury. Inflammatory cells in bronchoalveolar lavage fluid (BALF) were analyzed by cell differential counting on stained smears; enzyme-linked immunosorbent assay (ELISA)was used to measure the concentrations of proinflammatory cytokines in BALF; Histochemical and immunohistochemical staining were individually employed to detect eosinophils and IL-33+ cells in lung tissue. In vitro, different components derived from Edwardsiella tarda were used to stimulate pulmonary epithelial cells and macrophages, and concentrations of proinflammatory cytokines in the cell culture supernatant were also measured by ELISA. Results The bacterial lysates and metabolites of Edwardsiella tarda significantly increased the number of neutrophils and macrophages and the levels of the pro-inflammatory cytokines IL-1β, IL-6 and tumor necrosis factor α (TNF-α) in BALF; inactivated bacteria induced more eosinophils and IL-33⁺ cells infiltration in lung tissue. The different components of Edwardsiella tarda also stimulated production of proinflammatory cytokines by human and murine pulmonary epithelial cells and macrophages. Conclusion Edwardsiella tarda can cause pulmonary inflammatory response, possibly through inducing inflammatory cytokines by epithelial cells and macrophages.

Key words: Edwardsiella tarda, chronic obstructive pulmonary disease, inflammation, respiratory tract

中图分类号:

R392.9

李琴, 胡悦, 秦啸峰, 冯志红, 王炜, 孙英. 呼吸道迟缓爱德华菌不同组分对肺部炎症作用的对比分析[J]. 首都医科大学学报, doi: 10.3969/j.issn.1006-7795.2023.06.020.

Li Qin, Hu Yue, Qin Xiaofeng, Feng Zhihong, Wang Wei, Sun Ying. Comparative study of effect of different components of Edwardsiella tarda on pulmonary inflammation[J]. Journal of Capital Medical University, doi: 10.3969/j.issn.1006-7795.2023.06.020.

参考文献

［1］Christenson S A, Smith B M, Bafadhel M, et al. Chronic obstructive pulmonary disease［J］. Lancet, 2022, 399(10342)： 2227－2242.
［2］Celli B R, Wedzicha J A. Update on clinical aspects of chronic obstructive pulmonary disease［J］. N Engl J Med, 2019, 381(13)： 1257－1266.
［3］Wang Z, Maschera B, Lea S, et al. Airway host-microbiome interactions in chronic obstructive pulmonary disease［J］. Respir Res, 2019, 20(1)： 113.
［4］Yadava K, Pattaroni C, Sichelstiel A K, et al. Microbiota promotes chronic pulmonary inflammation by enhancing IL-17A and autoantibodies［J］. Am J Respir Crit Care Med, 2016, 193(9)： 975－987.
［5］Sethi S. Infection as a comorbidity of COPD［J］. Eur Respir J, 2010, 35(6)： 1209－1215.
［6］Ritchie A I, Wedzicha J A. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations［J］. Clin Chest Med, 2020, 41(3)： 421－438.
［7］Matkovic Z, Miravitlles M. Chronic bronchial infection in COPD. Is there an infective phenotype?［J］. Respir Med, 2013, 107(1)： 10－22.
［8］Pasquale M K, Sun S X, Song F, et al. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population［J］. Int J Chron Obstruct Pulmon Dis, 2012, 7： 757－764.
［9］Wu C T, Li G H, Huang C T, et al. Acute exacerbation of a chronic obstructive pulmonary disease prediction system using wearable device data, machine learning, and deep learning： development and cohort study［J］. JMIR Mhealth Uhealth, 2021, 9(5)： e22591.
［10］Suzuki K, Yanai M, Hayashi Y T, et al. Edwardsiella tarda bacteremia with psoas and epidural abscess as a food-borne infection： a case report and literature review［J］. Intern Med, 2018, 57(6)： 893－897.
［11］Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2023 report)［EB/OL］. ［2023－07－15］. https：//goldcopd.org/wp-content/uploads/2023/03/GOLD-2023-ver-1.3-17Feb2023_WMV.pdf.
［12］Wang Z, Locantore N, Haldar K, et al. Inflammatory endotype-associated airway microbiome in chronic obstructive pulmonary disease clinical stability and exacerbations： a multicohort longitudinal analysis［J］. Am J Respir Crit Care Med, 2021, 203(12)： 1488－1502.
［13］Leung K Y, Siame B A, Tenkink B J, et al. Edwardsiella tarda-virulence mechanisms of an emerging gastroenteritis pathogen［J］. Microbes Infect, 2012, 14(1)： 26－34.
［14］Schlenker C, Surawicz C M. Emerging infections of the gastrointestinal tract［J］. Best Pract Res Clin Gastroenterol, 2009, 23(1)： 89－99.
［15］Ma R, Su H L, Jiao K P, et al. Association between IL-17 and chronic obstructive pulmonary disease： a systematic review and meta-analysis［J］. Int J Chron Obstruct Pulmon Dis, 2023, 18： 1681－1690.
［16］Hilty M, Wüthrich T M, Godel A, et al. Chronic cigarette smoke exposure and pneumococcal infection induce oropharyngeal microbiota dysbiosis and contribute to long-lasting lung damage in mice［J］. Microb Genom, 2020, 6(12)： mgen000485.
［17］Wu X, Li R F, Lin Z S, et al. Coinfection with influenza virus and non-typeable Haemophilus influenzae aggregates inflammatory lung injury and alters gut microbiota in COPD mice［J］. Front Microbiol, 2023, 14： 1137369.
［18］Liang W J, Yang Y Q, Gong S H, et al. Airway dysbiosis accelerates lung function decline in chronic obstructive pulmonary disease［J］. Cell Host Microbe, 2023, 31(6)： 1054－1070.e9.
［19］Frach L, Jami E S, McAdams T A, et al. Causal inference methods for intergenerational research using observational data［J/OL］. Psychol Rev. ［2023－04－24］. https：//doi.org/10.1037/rev0000419.
［20］Luo J Y, Chen H A, Feng Y Y, et al. Blood eosinophil endotypes across asthma and chronic obstructive pulmonary disease (COPD)［J］. Can Respir J, 2022, 2022： 9656278.
［21］Yu S S, Zhang J, Fang Q H, et al. Blood eosinophil levels and prognosis of hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease［J］. Am J Med Sci, 2021, 362(1)： 56－62.
［22］David B, Bafadhel M, Koenderman L, et al. Eosinophilic inflammation in COPD： from an inflammatory marker to a treatable trait［J］. Thorax, 2021, 76(2)： 188－195.
［23］Xu X, Yu T, Dong L L, et al. Eosinophils promote pulmonary matrix destruction and emphysema via Cathepsin L［J］. Signal Transduct Target Ther, 2023, 8(1)： 390.
［24］Cayrol C, Girard J P. Interleukin-33 (IL-33)： a critical review of its biology and the mechanisms involved in its release as a potent extracellular cytokine［J］. Cytokine, 2022, 156： 155891.
［25］Li Q, Hu Y, Chen Y, et al. IL-33 induces production of autoantibody against autologous respiratory epithelial cells： a potential mechanism for the pathogenesis of COPD［J］. Immunology, 2019, 157(2)： 137－150.
［26］Shyam Prasad Shetty B, Chaya S K, Kumar V S, et al. Inflammatory biomarkers interleukin 1 beta (IL-1β) and tumour necrosis factor alpha (TNF-α) are differentially elevated in tobacco smoke associated COPD and biomass smoke associated COPD［J］. Toxics, 2021, 9(4)： 72.
［27］Barnes P J. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease［J］. J Allergy Clin Immunol, 2016, 138(1)： 16－27.
［28］Garth J, Barnes J W, Krick S. Targeting cytokines as evolving treatment strategies in chronic inflammatory airway diseases［J］. Int J Mol Sci, 2018, 19(11)： 3402.

[1]	李琴, 胡悦, 秦啸峰, 冯志红, 王炜, 孙英. 呼吸道迟缓爱德华菌不同组分对肺部炎症作用的对比分析[J]. 首都医科大学学报, 0, (): 1036-1043.
[2]	黎紫怡, 王玺, 梁璞. 雌激素调控固有免疫细胞功能的研究进展[J]. 首都医科大学学报, 2023, 44(2): 351-357.
[3]	靖学芳;吕喆;李晨;刘振龙;孙明洁;高燕;安云庆. BPI_m23-Fcγ1重组抗菌蛋白在CHO细胞中的表达及其对耐药菌的作用[J]. 首都医科大学学报, 2006, 27(2): 150-154.

呼吸道迟缓爱德华菌不同组分对肺部炎症作用的对比分析

Comparative study of effect of different components of Edwardsiella tarda on pulmonary inflammation

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 3

编辑推荐

Metrics

本文评价